Designing liposomal adjuvants for the next generation of vaccines

Research output: Contribution to journalArticle

View graph of relations Save citation

Open

Authors

Research units

Abstract

Liposomes not only offer the ability to enhance drug delivery, but can effectively act as vaccine delivery systems and adjuvants. Their flexibility in size, charge, bilayer rigidity and composition allow for targeted antigen delivery via a range of administration routes. In the development of liposomal adjuvants, the type of immune response promoted has been linked to their physico-chemical characteristics, with the size and charge of the liposomal particles impacting on liposome biodistribution, exposure in the lymph nodes and recruitment of the innate immune system. The addition of immunostimulatory agents can further potentiate their immunogenic properties. Here, we outline the attributes that should be considered in the design and manufacture of liposomal adjuvants for the delivery of sub-unit and nucleic acid based vaccines.

Documents

Details

Original languageEnglish
Pages (from-to)85-96
Number of pages12
JournalAdvanced Drug Delivery Reviews
Volume99
Issue numberPart A
Early online date11 Nov 2015
DOIs
Publication statusPublished - 1 Apr 2016

Bibliographic note

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: EPSRC, Aston University, Novartis and an Nc3R grant

    Keywords

  • liposomes, vaccines, adjuvants, antigens, delivery systems, microfluidics, QbD, MVA

Download statistics

No data available

Employable Graduates; Exploitable Research

Copy the text from this field...